Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the issuance of a new patent (Japanese patent number 6722453) covering SLS-002, aimed at treating anxiety from phobic disorders such as Specific Phobia and Social Phobia.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the issuance of a new patent (Japanese patent number 6722453) covering SLS-002, aimed at treating anxiety from phobic disorders such as Specific Phobia and Social Phobia. Additionally, the company received a Notice of Allowance for another patent application (Japanese patent number 2018-124196) that covers SLS-002's use in preventing anxiety before medical or dental procedures. These developments strengthen Seelos's intellectual property portfolio in the CNS disorder therapeutic area.
Positive
- Issuance of a new patent in Japan covering SLS-002 for treating anxiety in phobic disorders.
- Notice of Allowance for SLS-002 to prevent anxiety prior to medical or dental procedures.
Negative
- None.
Details
News Market Reaction – SEEL
The recorded move for SEEL in the trading session of this news was +4.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6722453) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE. The issued claims cover a formulation and method of using SLS-002 to treat patients experiencing anxiety due to phobic disorders such as: Specific Phobia, Agoraphobia, and Social Phobia.
Additionally, Seelos has received a Notice of Allowance from the Japanese Patent Office (Japanese patent application number 2018-124196) covering SLS-002 titled: ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE. The allowed claims cover a formulation and method of using SLS-002 to prevent anxiety in patients prior to medical or dental procedures.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-announces-issuance-of-a-new-patent-and-an-additional-notice-of-allowance-in-japan-for-intranasal-racemic-ketamine-sls-002-301129742.html
SOURCE Seelos Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.